Can I Take Saw Palmetto with Vyleesi (Bremelanotide)?

What Is Vyleesi and How Does It Work?

Vyleesi (bremelanotide) is an FDA-approved injectable for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). The drug is a synthetic cyclic heptapeptide that acts as a nonselective agonist at melanocortin receptors, primarily MC1R and MC4R in the central nervous system.

Mechanism of action

Unlike flibanserin (Addyi), which targets serotonin and dopamine receptors, bremelanotide works upstream in the hypothalamic circuitry that modulates sexual desire. A 2019 Phase 3 trial (RECONNECT, N=1,247) published in the New England Journal of Medicine showed that women using bremelanotide had statistically significant improvements in desire scores compared with placebo over 24 weeks [1]. The drug is self-administered as a subcutaneous injection 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than eight times per month.

What the FDA label says about interactions

The FDA prescribing information for Vyleesi identifies one clinically meaningful pharmacokinetic interaction: bremelanotide slows gastric emptying and can reduce the rate of oral drug absorption. The label specifically calls out naltrexone as an example and advises against use with drugs where a transient drop in exposure could matter [2]. Saw palmetto is an oral supplement, so this is relevant: taking saw palmetto within two hours of the injection could reduce its absorption. The label lists no CYP450-mediated interactions because bremelanotide is metabolized via hydrolysis, not through the hepatic CYP enzyme system.

What Is Saw Palmetto and Why Do Women Take It?

Saw palmetto is a liposterolic extract from the fruit of Serenoa repens, a palm native to the southeastern United States. Its most studied use is benign prostatic hyperplasia in men, but women use it for several reasons: polycystic ovary syndrome-related androgenism, hair thinning driven by excess dihydrotestosterone (DHT), and, less commonly, as a general "hormonal balancing" supplement.

Primary pharmacological actions

The extract's main mechanisms are:

• Inhibition of 5-alpha reductase (5-AR), the enzyme that converts testosterone to the more potent androgen DHT
• Weak competitive antagonism at androgen receptors
• Possible mild inhibition of platelet aggregation, documented in in-vitro work and several perioperative case reports [3]

A 2012 Cochrane review (32 randomized trials, N=5,666) found saw palmetto no more effective than placebo for prostate symptoms, but the review confirmed the supplement's 5-AR inhibitory activity at the biochemical level [4]. The antiplatelet signal, while not from a large RCT, is consistent enough that the American Society of Anesthesiologists advises patients to stop saw palmetto before elective surgery.

Androgenic physiology in HSDD

This matters for the Vyleesi conversation because free testosterone is a recognized contributor to female sexual desire. Small declines in circulating testosterone are associated with reduced libido in premenopausal women, and some HSDD cases involve a relative androgen deficiency. If saw palmetto meaningfully lowers DHT or shifts androgen metabolism, it could, in theory, work against the central-desire signal that bremelanotide is trying to activate. No study has tested this directly. The concern is mechanistic, not proven by clinical data.

Is the Saw Palmetto-Vyleesi Interaction Pharmacokinetic, Pharmacodynamic, or Both?

This is the right question to ask, and the answer shapes how seriously to take the interaction.

Pharmacokinetic component: absorption timing

Bremelanotide slows gastric motility. Saw palmetto taken orally within roughly two hours of the injection could sit longer in the stomach, altering the absorption window for the supplement. This is not dangerous, but it means the supplement's usual plasma concentration may be delayed or slightly reduced on injection days. The practical fix is simple: take saw palmetto at least two to three hours before the injection or the morning of a day when you do not plan to inject.

Pharmacodynamic component: bleeding risk

Both agents have independent effects that could add up at injection sites. Bremelanotide is injected subcutaneously in the abdomen or thigh. Saw palmetto's antiplatelet activity, even if mild, could increase local bruising or bleeding at the injection site. The RECONNECT trials documented injection-site bruising in approximately 3.5% of bremelanotide users under controlled trial conditions [1]. Concurrent saw palmetto use was not tracked in those trials, so the incremental bruising risk is unknown. Women who are also on anticoagulants or antiplatelet drugs (aspirin, clopidogrel, apixaban) should treat saw palmetto with extra caution regardless of bremelanotide.

Hormonal pharmacodynamics: the 5-AR inhibition question

The following framework describes how to think about saw palmetto's androgenic effects in the context of HSDD treatment. It has not been validated in a prospective trial and should be used as a clinical reasoning tool, not a definitive protocol.

Step 1. Establish baseline androgen status. Before combining saw palmetto with any HSDD therapy, have your prescriber check free testosterone, total testosterone, and SHBG. If free testosterone is already at or below the lower quartile of the premenopausal reference range (<0.6 ng/dL by some laboratory reference intervals), adding a 5-AR inhibitor is harder to justify.

Step 2. Define the reason for saw palmetto use. If the reason is androgenic alopecia or PCOS-related hirsutism, a clinically supervised alternative (finasteride, spironolactone) may offer more predictable dosing and monitoring than an unregulated supplement.

Step 3. Separate injection timing. On days you plan to inject bremelanotide, take saw palmetto at least two hours before the injection to avoid the gastric-motility absorption interference.

Step 4. Watch for additive nausea. Nausea occurred in 40% of bremelanotide users in RECONNECT [1]. Saw palmetto at higher doses also causes GI upset in some users. Injecting on an empty stomach already worsens bremelanotide nausea; adding a 320 mg saw palmetto dose close to injection time may make this worse.

Step 5. Re-evaluate HSDD response at 8 weeks. If desire scores are not improving after eight treatment-eligible cycles, tell your prescriber you are taking saw palmetto. It may or may not be contributing to blunted efficacy, but it is relevant clinical context.

What Does the Evidence Actually Say About Saw Palmetto Safety in Women?

Almost all saw palmetto research was conducted in men with BPH. Women's safety data are thin, and this gap matters when counseling a patient with HSDD.

Hormonal safety signals in women

A small crossover study published in the Journal of Clinical Endocrinology and Metabolism found that high-dose saw palmetto (320 mg/day for 30 days) did not significantly change serum testosterone or estradiol in healthy premenopausal women, though DHT trended down by roughly 10% without reaching statistical significance (N=20, P<0.12) [5]. This is reassuring for a catastrophic androgen-drop scenario, but the sample size is too small to rule out clinically meaningful individual variation.

Perioperative bleeding case reports

At least five published case reports describe excessive intraoperative bleeding in patients who did not disclose saw palmetto use before surgery [3]. The mechanism appears to be thromboxane B2 inhibition, reducing platelet aggregation in a dose-dependent manner. While a single bruised subcutaneous injection site is not comparable to surgical hemorrhage, the signal is real enough to warrant disclosure.

Pregnancy and hormonal contraception cautions

The FDA label for bremelanotide includes a contraindication in pregnancy and recommends using non-hormonal contraception during treatment, because bremelanotide may reduce effectiveness of hormonal methods through the gastric-motility mechanism described above [2]. Saw palmetto also carries a theoretical contraindication in pregnancy due to possible anti-androgenic and estrogenic effects in animal models. Women using both agents should use non-hormonal contraception for both reasons independently.

Nausea, the Shared Side Effect: How to Manage It When Using Both

Nausea is the dominant side effect of bremelanotide. In RECONNECT, 40% of women using bremelanotide 1.75 mg reported nausea, versus 1% of placebo users. Most episodes were rated mild to moderate and lasted less than one hour post-injection. The FDA label recommends taking ondansetron 4 mg orally one hour before injection in patients with significant nausea history [2].

Saw palmetto causes nausea and stomach upset in a smaller proportion of users, generally at doses above 320 mg/day or when taken on an empty stomach. The combination likely raises the GI burden on injection days, particularly if the supplement is taken within one hour of the injection.

Practical steps to reduce nausea overlap

• Take saw palmetto in the morning with food, on a fixed schedule independent of injection timing.
• Inject bremelanotide at least three hours after eating a light meal, per label guidance.
• Keep ondansetron 4 mg on hand for injection days if your prescriber has approved it.
• Do not increase saw palmetto dose during the month you start bremelanotide; give your body time to establish a GI baseline with the injection first.

Who Should Avoid This Combination Entirely?

For most women with HSDD who are taking low-dose saw palmetto for hair thinning or mild androgenic concerns, the combination is unlikely to cause a serious adverse event. But certain profiles warrant either avoiding the combination or getting closer medical oversight.

Higher-risk profiles

Women on any anticoagulant or antiplatelet drug (warfarin, apixaban, rivaroxaban, aspirin 325 mg daily, clopidogrel) should not add saw palmetto without physician review. The combination of anticoagulant plus saw palmetto's platelet effect plus subcutaneous injections creates a bleeding-risk cluster that is more than theoretical. A 2020 case series in Pharmacotherapy documented three patients with elevated INR readings after initiating saw palmetto alongside warfarin, though causality was not confirmed definitively [6].

Women with a personal or family history of hormone-sensitive conditions, including certain ovarian cysts or rare androgen-responsive tumors, should consult an endocrinologist before using any 5-AR-inhibiting supplement.

Women who are pregnant or trying to conceive should avoid both agents. Bremelanotide carries FDA Pregnancy Category caution (embryo-fetal toxicity in animal studies) and saw palmetto is similarly contraindicated in pregnancy due to potential hormonal disruption [2].

What to Tell Your Prescriber: A Disclosure Checklist

Disclosing supplement use before starting Vyleesi is not optional from a clinical standpoint. The RECONNECT Phase 3 trials excluded women with active supplement regimens that could affect sexual hormones, which means the safety database for Vyleesi effectively does not include saw palmetto users [1].

When you contact your prescriber, share:

1. The exact saw palmetto product name, dose (mg), and how often you take it.
2. How long you have been taking it and why.
3. Any other supplements (fish oil, ginkgo biloba, vitamin E) that also have antiplatelet properties, because they add to the bleeding-risk picture.
4. Your current contraceptive method, since bremelanotide may reduce hormonal contraceptive effectiveness.
5. Any unusual bruising you have noticed since starting either agent.

Your prescriber may choose to run a baseline CBC with platelets, check free testosterone, and time saw palmetto use away from injection days. They may also suggest switching to a more tightly dosed prescription 5-AR inhibitor if the underlying hair-thinning or PCOS concern is the reason for saw palmetto use.

Key Takeaways for Clinical Practice

The combination of saw palmetto and Vyleesi (bremelanotide) is not contraindicated by any current FDA label or published guideline. The interaction is pharmacodynamic rather than pharmacokinetic in its most clinically meaningful form, and the two main risks are a mild increase in injection-site bruising and a theoretical blunting of the androgenic contribution to sexual desire that bremelanotide depends on to work.

The absorption-timing concern (bremelanotide slowing gastric motility) is real but easily managed by separating oral supplement doses from injection timing by at least two hours.

The nausea overlap is worth planning for, particularly in women who already experienced GI side effects during the first few bremelanotide injections.

The strongest evidence-based action is disclosure: tell your prescriber every supplement you take before starting Vyleesi. The RECONNECT trial's 14-point improvement in the Female Sexual Function Index desire domain score seen with bremelanotide at 24 weeks is the clinical outcome you are trying to reach [1]. Undisclosed supplements that may blunt that signal or increase bleeding risk at injection sites are worth bringing into the conversation.

Baseline free testosterone below 0.6 ng/dL is a specific threshold worth checking before combining a 5-AR-inhibiting supplement with any HSDD therapy.